SGLT2 inhibitors significantly inhibit osteosarcoma tumour growth and induce immune cell infiltration in vivo by upregulating STING expression and activating the IRF3/IFN-β pathway, which could be attributable to the inhibition of AKT phosphorylation (141). Here, SLC5A2 is linked to neoplasm.